Patients with stable, symptomatic hf n5010 who were on prescribed hf therapy and had lv. There were 530 deaths in elite ii and 906 deaths in val heft. Five thousand and ten patients with stable, symptomatic hf, who were on prescribed hf therapy, with left ventricular lv ejection fraction 2. Valheft and angiotensinreceptor blockers in perspective. In the valsartan heart failure trial val heft, which evaluated the efficacy of valsartan in patients with moderate to severe hf, blood was sampled for brain natriuretic peptide bnp and ne assay in all patients at baseline and at 4, 12, and 24 months during followup. The valsartan heart failure trial valheft was a randomized, placebocontrolled, doubleblind, parallelgroup trial. The africanamerican heart failure trial a heft, which was conducted only in patients with advanced hf who identified themselves as african american, compared a fixed dose combination of isosorbide dinitrate isdn plus hydralazine with placebo in addition to standard therapy. In the subsequent vheft ii, survival was greater with enalapril than. Lessons learned from the valsartan heart failure trial. Sep 19, 2001 the losartan heart failure survival study elite ii and the valsartan heart failure trial val heft both evaluated the efficacy and tolerability of a selective angiotensin ii receptor antagonist on morbidity and mortality in patients with symptomatic heart failure. The aims of these subanalyses of val heft were to assess a the effects of valsartan in the prevention of af, b the independent predictors of this event, and c the prognostic role of af occurrence. The africanamerican heart failure trial aheft was a randomized, placebocontrolled, doubleblind trial with patients recruited at 161 centers in the united states.
A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. The target in guideit was set on ntprobnp levels of below 1,000 ngl, as initiated from the val heft trial results including patients with ejection fraction val heft trial in the placebo group at 4 months from baseline, and subsequent mortality was oct 11, 2011 a trial should be initiated and continued only if the anticipated benefits justify the risks. Published in nejm in 2001, the valheft trial was a randomized, doubleblinded, placebocontrolled, trial involving 302 centers in 16 countries. Konstam md cohn jn tognoni g for the valsartan heart failure trial investigators. For example, the valsartan heart failure trial valheft and the candesartan in heart failure. The aims of these subanalyses of valheft were to assess a the effects of valsartan in the prevention of af, b the independent predictors of this event, and c the prognostic role of af occurrence. These beneficial effects are additional to those of evidencebased treatments for acute myocardial infarction including ace inhibitors. A second large trial, val heft, was presented at the scientific sessions of the american heart association in 2000. Val heft and angiotensinreceptor blockers in perspective.
However, two subgroup analyses have probably made this interpretation too simplistic. Comments on guideit, a randomized study of natriuretic. The mean dose of losartan in elite ii was 44 mg vs 254 mg. Severity of left ventricular remodeling defines outcomes and. The valheft study was a randomized, placebocontrolled, doubleblind, parallelarm multicenter trial. The recently completed valsartan in heart failure trial valheft examined 5000 patients with mildtomoderate heart failure and showed that valsartan, when added to an ace inhibitor, reduced heart. Effects of valsartan on circulating brain natriuretic peptide. Valsartan reduces the incidence of atrial fibrillation in. Results in the elite ii trial, 79% of patients achieved the target dose of test medication, compared with 80% in the valheft study. Background actions of angiotensin ii may contribute to the progression of heart failure despite treatment with currently recommended drugs. Changes in brain natriuretic peptide and norepinephrine.
Effect of carvedilol on outcome after myocardial infarction. Published in nejm in 2001, the val heft trial was a randomized, doubleblinded, placebocontrolled, trial involving 302 centers in 16 countries. Vheft ii, 1991 trial summary pdf trial summary a randomised clinical trial investigating the effect of versus enalapril in men with chronic congestive heart failure and cardiac dilatation ct ratio0. Valheft study was not treated with an ace inhibitor.
Valheft investigators prognostic value of changes in nterminal probrain natriuretic peptide in valheft valsartan heart failure trial. Can valsartan reduce the occurrence of atrial fibrillation in. Appendix drug class risk ratio drug versus placebo 95%ci trials included in the metaanalysis treatment effect on mortality acei 0. The valheft study included 5009 patients with a mean age of 62. Vheft vasodilatorheart failure trial, the original clinical trial of the combination, tested a concept, not a pill. Significantlyreduced mortality and morbidityimproved signs and symptoms adverse effects for those valsartan, acei and betablockerincreased mortality and morbidity. Val heft randomised 5010 patients, the clinical characteristics of whom are summarised in table 3.
Utility of aminoterminal probrain natriuretic peptide. Val heft was a randomized, placebocontrolled, doubleblind, parallelarm multicenter trial. Anemia and change in hemoglobin over time related to. Direct comparison of btype natriuretic peptide bnp and. The complete description of the valheft trial is contained in previous publications. The new drugs for the treatment of heart failure maria rosa costanzo, m. The rationale for this was that ntprobnp has a longer halflife 6 h vs. The occurrence of af was evaluated based on adverse event reports in the patients with hf enrolled in val heft. Sex differences in clinical characteristics and longterm.
Effects of candesartan in patients with chronic heart. The valsartan heart failure trial val heft was a randomized, placebocontrolled, doubleblind, parallelgroup trial. Effects of candesartan in patients with chronic heart failure. Importance of charm in relation to other heart failure trials with arbs h59. Valsartan heart failure trail val heft investigators. Valsartan benefits left ventricular structure and function. The second evaluation of losartan in the elderly trial. Lessons learned from the valsartan heart failure trial val. A hard look at angiotensin receptor blockers in heart failure core. Valheft was a randomized, placebocontrolled, doubleblind, multicenter trial in patients with symptomatic hf that evaluated the efficacy of the angiotensin receptor blocker valsartan.
Use of isosorbide dinitrate and hydralazine in african. A randomized trial of the angiotensinreceptor blocker. Valsartan benefits left ventricular structure and function in. Angiotensin ii receptor antagonists for the treatment of heart failure. Atrial fibrillation guideline summary annals of family. Both elite ii and valheft evaluated the efficacy of a selective angiotensin ii receptor antagonist on morbidity and mortality in patients with symptomatic heart failure. The losartan heart failure survival study elite ii and the valsartan heart failure trial valheft both evaluated the efficacy and tolerability of a selective angiotensin ii receptor antagonist. The objectives of the valsartan in heart failure trial val heft were to assess the effect of the addition of valsartan novartis pharma ag, basel, switzerland, an angiotensin receptor blocker arb, on mortality and morbidity, and on secondary end points, including signs and symptoms, quality of life, and neurohormonal and echocar. In the valsartan heart failure trial valheft, which evaluated the efficacy of valsartan in patients with moderate to severe hf, blood was sampled for brain natriuretic peptide bnp and ne assay in all. The valsartan heart failure trial val heft is the first largescale randomized, multinational clinical study to assess the efficacy and safety of valsartan, an angiotensin ii receptor blocker. A tale of the blind man and the elephant author links open overlay panel marvin a. A total of 5,010 patients with stable, symptomatic hf who were on prescribed hf therapy and had left ventricular ejection fraction lvef jun 01, 2000 val.
In patients treated longterm after an acute myocardial infarction complicated by leftventricular systolic dysfunction, carvedilol reduced the frequency of allcause and cardiovascular mortality, and recurrent, nonfatal myocardial infarctions. The rights, safety, and wellbeing of the trial subjects are the most important considerations and should prevail over interests of science and society. Materials and methods study design and patients valheft was a randomized, placebocontrolled, doubleblind, parallelarm multicenter trial. In this study, we carried out a direct comparison of the 2 natriuretic peptides in this large population in relation to the severity of the disease and clinical outcome. Amgen cardiovascular proudly sponsors heart science amplified. Pdf importance of charm in relation to other heart.
Val heft enrolled 5010 patients, mainly new york heart association nyha functional class ii and iii with low ejection fraction and evidence of left ventricular dilatation. Combination of isosorbide dinitrate and hydralazine in. Effects of valsartan on circulating brain natriuretic. The africanamerican heart failure trial a heft was a randomized, placebocontrolled, doubleblind trial with patients recruited at 161 centers in the united states. Val heft was an international, randomized, multicenter, doubleblind trial that compared valsartan and placebo added to prescribed treatment in 5010 patients with chronic heart failure nyha class. Download it once and read it on your kindle device, pc, phones or tablets. Val heft was a randomized, placebocontrolled, doubleblind, multicenter trial in patients with symptomatic hf that evaluated the efficacy of the angiotensin receptor blocker valsartan. Changes in brain natriuretic peptide and norepinephrine over. The valsartan heart failure trial val heft showed that valsartan reduced the risk of first worsening hf hospitalization by 27. As expected, annualized hospitalizations for heart failure in the. Manipulation of the reninangiotensin system circulation. The available nonclinical and clinical information on an investigational product should.
Valsartan did not reduce mortality but did significantly reduce the combined morbidity. Valsartan reduces atrial fibrillation in patients with heart. Patients with stable, symptomatic hf n5010 who were on prescribed hf therapy and had lv ejection fraction 2. Severity of left ventricular remodeling defines outcomes. The valsartan heart failure trial valheft showed that valsartan reduced the risk of first worsening hf hospitalization by 27. Valsartan reduces atrial fibrillation in patients with. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. The mean dose of losartan in elite ii was 44 mg vs 254 mg of valsartan in val heft. Angiotensin receptor blockers for chronic heart failure and. In patients not receiving ace inhibitors, valsartan significantly improves mortality. Use features like bookmarks, note taking and highlighting while reading heft.
Angiotensin receptor blockers for chronic heart failure. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure. The valsartan heart failure trial val heft was carried out in over 5,000 patients with hf, all of whom had core laboratorymonitored echocardiography performed at baseline and during followup after randomization to valsartan or placebo, in addition to all background hf therapy. Patients at 302 centers in 16 countries gave written informed. A total of 5,010 patients with documented left ventricular dilatation and at least two weeks of treatment with ace inhibitors, diuretics, digoxin, or beta. Nov 01, 2002 in designing the valsartanheart failure trial val heft, we began with the fundamental understanding that ace inhibitors exert favorable effects on.
Can valsartan reduce the occurrence of atrial fibrillation. Results in the elite ii trial, 79% of patients achieved the target dose of test medication, compared with 80% in the val heft study. Firstly,a very large 45% reduction in mortalitymorbidity in the small 7% subset of patients not taking an acei at baseline has led some to question whether most of the benefit in. Valheft was a randomized, placebocontrolled, doubleblind, parallelarm multicenter trial. The vasodilatorheart failure trial i v heft i sought to explore the effects of using a combination of hydralazine and isosorbide dinitrate in managing heart failure. The losartan heart failure survival study elite ii and the valsartan heart failure trial val heft both evaluated the efficacy and tolerability of a selective angiotensin ii receptor antagonist. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure valheft. At face value, val heft,therefore,seems to be a positive trial. Combination of isosorbide dinitrate and hydralazine in blacks. The valsartan heart failure trial valheft was a randomized.
The objectives of the valsartan in heart failure trial valheft were to assess the effect of the addition of valsartan novartis pharma ag, basel, switzerland, an angiotensin receptor blocker arb, on. The complete description of the val heft trial is contained in previous publications. Valheft valsartan in heart failure trial is summarized in this section including the primary endpoint and results. The principal results of the val heft trial, as presented at the aha, are shown in table 5. The valsartan heart failure trial val heft established that the angiotensin receptor blocker valsartan is effective for reducing morbidity and slowing the progression of heart failure in patients already taking angiotensinconverting enzymes or beta blockers. In summary, this trial demonstrated that treating patients with congestive heart failure with hydralazineisosorbide dinitrate significantly reduced mortality when compared with. Prognostic value of soluble suppression of tumorigenicity. Apr 01, 2003 the valsartan heart failure trial val heft established that the angiotensin receptor blocker valsartan is effective for reducing morbidity and slowing the progression of heart failure in patients already taking angiotensinconverting enzymes or beta blockers. Val heft was a randomized, placebocontrolled, doubleblind, parallelarm multicentre trial. Prognostic value of soluble st2 in the valsartan heart failure trial. The target in guideit was set on ntprobnp levels of below 1,000 ngl, as initiated from the valheft trial results including patients with ejection fraction sep 07, 2017. The trials differed, however, in terms of their primary hypothesis, study design, and treatment regimens, and this must be taken. The valsartan in heart failure trial valheft has been designed to test the efficacy and safety of the at1 receptor. A hard look at angiotensin receptor blockers in heart failure.
417 206 833 852 910 434 222 1086 372 964 713 46 1443 526 248 479 38 1027 990 321 1378 830 171 124 970 864 438 1474 386 1088 959 291 855 846 370 967 1519 1639 937 978 763 113 1465 1086 1098 210